Physician profile
Ryan Hagens
NPI 1073008991
$2,942.66
in general payments reported to CMS, 2019-2025
16 companies · $981 in 2025
The $981 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,101 · 2023: $721 · 2024: $140 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259 · Travel and Lodging: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.40 |
| Travel and Lodging | $582.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,276.28 | 2022-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $616.40 | 2022-2025 | Superion Indirect Decompression System, General - Pain Management, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $254.54 | 2023 | Proclaim |
| Vertos Medical, INC. | $136.58 | 2022 | |
| Abbvie INC. | $128.51 | 2022 | |
| Nalu Medical, INC. | $126.17 | 2022 | |
| Si-Bone, INC. | $99.39 | 2023 | |
| Lundbeck LLC | $48.33 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.28 | 2024 | Relistor |
| Nevro Corp. | $46.24 | 2023-2024 | Senza |
| Collegium Pharmaceutical, INC. | $40.73 | 2023 | Xtampza |
| Merz Pharmaceuticals, LLC | $38.41 | 2023 | Xeomin |
| Averitas Pharma INC. | $21.09 | 2025 | Qutenza |
| Almatica Pharma LLC | $20.91 | 2023 | Gralise |
| Scilex Pharmaceuticals INC. | $20.61 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $20.19 | 2023 | Levorphanol Tartrate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hagens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.